Jack Sipperley, MD
Retina Specialist · Phoenix, AZNPI 1235130402
Payments from drug & device makers
What this record shows
This record is dominated by other: $8,808 of the $12,789 with a category attached, or 68.9%. Carl Zeiss Meditec USA, Inc. accounts for 68.9% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2022 at $6,325 and has fallen 97.9% since, to $132 in 2025. That places this record below the midpoint for retina specialist clinicians in AZ, where the typical reported total is $12,789.
Across 47 payments — averaging $272.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Carl Zeiss Meditec USA, Inc.$9K
- Alimera Sciences, Inc.$2K
- Genentech USA, Inc.$532
- Regeneron$351
- Novartis$248
- Biogen$149
- plus $671 from 9 others
Across 17 payments — averaging $23,309 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$359K
- Genentech, Inc.$23K
- AbbVie$15K
What the payments were for
- Food & beverage$3,98131%
- Other$8,80869%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Carl Zeiss Meditec USA, Inc. | 2 | $8,808 |
| Alimera Sciences, Inc. | 6 | $2,029 |
| Genentech USA, Inc. | 8 | $532 |
| Regeneron | 5 | $351 |
| Novartis | 3 | $248 |
| Biogen | 2 | $149 |
| Regeneron Healthcare Solutions, Inc. | 7 | $149 |
| Hoffmann-la Roche Limited | 1 | $125 |
| Alcon | 2 | $108 |
| Apellis Pharmaceuticals, Inc. | 1 | $100 |
| Bausch & Lomb Americas Inc. | 4 | $76 |
| Astellas Pharma US Inc | 2 | $42 |
| Mallinckrodt Enterprises LLC | 2 | $37 |
| Genentech, Inc. | 1 | $18 |
| AbbVie | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CIRRUS HD-OCT$4,485
- CIRRUS 5000$4,323
- Iluvien$2,029
- VABYSMO$268
- BEOVU$231
- SUSVIMO$144
- XIIDRA$116
- Syfovre$100
How this compares
$12,789 in reported general payments places this provider in the 50th percentile of 30 retina specialist providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 13 | $12,664 |
| Prednisolone Acetate | 322 | $9,477 |
| Ofloxacin | 229 | $2,301 |
| Brimonidine Tartrate | 36 | $1,417 |
| Atropine Sulfate | 18 | $1,013 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 145 | $596 |
| Latanoprost | 83 | $593 |
| Dorzolamide Hcl | 25 | $411 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 38 | $406 |
| Timolol Maleate | 30 | $380 |
| Ketorolac Tromethamine | 21 | $201 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 14 | $160 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $15 | $12,66413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 30 retina specialist providers in Arizona.
Other retina specialist in Phoenix
- Jordan GraffPhoenix$483K
- Rahul ReddyPhoenix$333K
- Henry KwongPhoenix$147K
- Benjamin BakallPhoenix$137K
- Jaime GaitanPhoenix$114K
- Stephen de SouzaPhoenix$95K
- Joseph BryanPhoenix$88K
- Alan GordonPhoenix$86K
- Suhail AlamPhoenix$24K
- Rima PatelPhoenix$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.